Article
25 Jul 2022
In Through The Out Door: FDA Issues Guidance On Its Importation Of Prescription Drugs Final Rule
AUTHORS CONTENT
Article
14 Jul 2022
It's A Heartache: FDA's OPDP Issues An Untitled Letter For Unlawful Promotion Of A Cholesterol-Lowering Drug Product
Article
14 Jul 2022
Break On Through To The Other Side, Part 2: FDA Issues Draft Guidance About Breakthrough Therapy Designation Rescission
Article
28 Apr 2022
A Change Is Gonna Come: AdvaMed Revises Its Code Of Ethics On Interactions With Health Care Professionals
Article
19 Apr 2022
Out Of Touch: FDA Takes Exception With Drug Company's Promotion For Topical Drug Product
Article
31 Mar 2022
Don't Go Changing . . . Unless You Ask FDA
Article
31 Mar 2022
Roll With The Changes: FDA's Proposed Amendments To Converge Its Quality Management System Requirements With ISO Requirements
Article
30 Mar 2022
What's That Smell? California Safe Cosmetics Program Wants To Know
Article
04 Mar 2022
Slow Down, You Move Too Fast: OPDP Issues A Warning Letter For Promoting An Investigational New Drug
Article
04 Mar 2022
The Room Where It Happens: FDA Issues Draft Guidance On Formal Meetings Between FDA And Sponsors Of OTC Monograph Drugs
Article
24 Feb 2022
Tell Me, I've Got To Know: FDA Issues Draft Guidance On 506J Notifications For Medical Devices
Article
24 Feb 2022
Freeze-Frame: FDA Issues An Untitled Letter For An Unlawful Instagram Post
Article
23 Feb 2022
You Cannot Do It Any Way You Want It: FDA Issues An Untitled Letter For An Incomplete Journey Forward
Article
23 Feb 2022
It's The Little Things: FDA Issues A Warning Letter For Improper Drug Listing